STOK Stoke Therapeutics, Inc. Loading...

From BIIB earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:30
Jul 29 ◎
Chris Viehbacher President and Chief Executive Officer, Biogen Inc. BIIB Q2 FY26 call
Biogen's partner Stoke has a Phase 3 readout for Dravet Syndrome within the next four quarters, a key pipeline catalyst for Biogen.
STOK
HIGH
12:00
Apr 29 ◎
Robin Kramer Chief Financial Officer, Biogen Inc. BIIB Q1 FY26 call
Biogen's collaboration with Stoke Therapeutics on a Dravet syndrome treatment requires significant upfront payments, reflecting a costly R&D partnership.
STOK
HIGH
13:30
Feb 06 ◎
Chris Viehbacher President and Chief Executive Officer, Biogen Inc. BIIB Q4 FY25 call
Stoke's pipeline and upcoming data readout are a potential future catalyst for the partnership.
STOK
HIGH

About STOK Analyst Coverage

Buzzberg tracks STOK (Stoke Therapeutics, Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Latest voices: Chris Viehbacher, Robin Kramer.